Antibiotics

Microbiome Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of 233 Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Biotechnology, Pharmaceutical, Health, Record, Research, Confidentiality, Chapter Six, Intellectual property, Chapter Five, A-Z, Chapter Two, Chapter Four, Hyperlink, Orientation, Chapter Three, Directory, Chapter One, Antibiotics, Risk management, Real estate, Property management, Commercial property, Lease

Microbiome Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the microbiome deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Microbiome Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the microbiome deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of microbiome deals from 2016 to 2023.
  • The report provides a detailed understanding and analysis of how and why companies enter microbiome deals.
  • The report also includes numerous table and figures that illustrate the trends and activities in microbiome deal making since 2016.

RootPath Announces Its Custom Gene Library, Slashing Gene Synthesis Cost by More Than Half

Retrieved on: 
Tuesday, November 21, 2023
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Synthetic biology, AI, Library, Pathfinder, Multimedia, PUC19, Gene, Drug development, Fine chemical, Antibiotics

RootPath announced today the US launch of its flagship product, RootPath Custom Gene Library.

Key Points: 
  • RootPath announced today the US launch of its flagship product, RootPath Custom Gene Library.
  • Similar to conventional gene synthesis products, this product is delivered as individual, sequence-verified plasmids in 96- or 384-well plates.
  • Currently, standard RootPath Custom Gene Library supports gene lengths from 450 bp to 2.5 kb.
  • RootPath Custom Gene Library was launched in China earlier this year and was met with broad enthusiasm.

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Retrieved on: 
Friday, November 17, 2023
Science, Biotechnology, Research, Oncology, Health, Data Management, Technology, Genetics, TMB, GCN, Multimedia, Whole genome sequencing, Personalized medicine, Conference, Treatment of lung cancer, Diagnosis, MET, Insight, NGS, Biomarker, Poster, AACR, NSCLC, Antibiotics, Cancer, Hong Kong

Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

Key Points: 
  • Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.
  • (Photo: Business Wire)
    Genome Insight's presentation will feature the outcomes of a collaborative real-world evidence program on TE-WGS in lung cancers.
  • Genome Insight will present the case of a 78-year-old Asian man from Hong Kong with poorly differentiated Non-Small Cell Lung Cancer (NSCLC).
  • "We are thrilled to present this real-world evidence from Hong Kong at the esteemed 2023 AACR-KCA Joint Conference," said Ryul Kim, Chief Technology Officer.

Phase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid Leukemia

Retrieved on: 
Friday, November 17, 2023
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Karyotype, Chromosome, Plant, Acute myeloid leukemia, Collection, Risk, CMA, Cytogenetics, Phase Genomics, Animal, Genomics, Metagenomics, Booth, Genome, Risk assessment, Cancer, AML, Antibiotics, Medical imaging

The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).

Key Points: 
  • The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML).
  • Phase Genomics addresses these legacy challenges with the combination of its OncoTerra technology and Element’s AVITI system for next-generation sequencing, providing a high-resolution alternative for comprehensive, streamlined risk stratification in the research setting.
  • The next-generation cytogenomics all-in-one approach is primed to replace fragmented legacy tests with a single, rapid assay,” said Ivan Liachko, founder and CEO of Phase Genomics.
  • Discover more about next-generation cytogenomics powered by proximity ligation technology in four presentations at AMP23 , or connect with the Phase Genomics team at Booth 810.

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

Retrieved on: 
Tuesday, November 14, 2023
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Investment, Therapy, Gram, Patient, Medicine, University of Strathclyde, Death, University of Oxford, Laboratory, Klebsiella pneumoniae, GSK, Bacteria, Collateral damage, AMR, Klebsiella, University, Pseudomonas aeruginosa, University of Glasgow, Innovation, Physician, Scottish Enterprise, Pharmaceutical industry, Antibiotics, Entrepreneurship, Bacteriocin

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Key Points: 
  • Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
  • **
    Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins.
  • Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics.
  • “This seed funding is testament to the promise of Glox Therapeutics’ precise antibiotic therapies, and we are thrilled to have the backing of such high-calibre investors.

New 2-gram Meropenem for Injection, USP Vial Exclusive from WG Critical Care, LLC

Retrieved on: 
Tuesday, December 5, 2023
Patient safety, Nursing, USP, Injection, WGCC, IQVIA, Patient, FDA, Workflow, Hospital, Critical care, Pharmaceutical industry, Antibiotics, Pharmacist, Meropenem

Meropenem is the sixth largest generic anti-infective product in unit volume in hospital and alternate site settings.

Key Points: 
  • Meropenem is the sixth largest generic anti-infective product in unit volume in hospital and alternate site settings.
  • According to a 2022 IQVIA report, the market value for Meropenem is $88.7 million dollars, with unit volume at 15.9 million annually.
  • "Until now, the only way to provide a 2-gram dose was to mix two 1-gram vials or four 500-milligram vials.
  • The WGCC 2g Meropenem for injection, USP vial is free of natural rubber latex and bar coded at the unit-of-use.

KromaTiD and SeQure Dx Enter Partnership Agreement to Offer Comprehensive, IND-Enabling Gene Editing Services Supporting Cell and Gene Therapy Research

Retrieved on: 
Thursday, November 30, 2023
DGH, Research, Safety, Gene editing, IND, Data, Patient, Investigational New Drug, Genome, Partnership, Genomics, Antibiotics

LONGMONT, Colo. and WALTHAM, Mass., Nov. 30, 2023 /PRNewswire/ -- KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell and gene therapy research, Investigational New Drug (IND) applications and drug product development.

Key Points: 
  • LONGMONT, Colo. and WALTHAM, Mass., Nov. 30, 2023 /PRNewswire/ -- KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell and gene therapy research, Investigational New Drug (IND) applications and drug product development.
  • The combination of SeQure Dx's NoteSeQ™and ScopeSeQ™ platforms with KromaTiD's dGH in-Site™, dGH SCREEN™ and Genomic Integrity Karyotyping™ services provides the world's first comprehensive, one-stop gene editing evaluation solution.
  • KromaTiD has developed a menu of commercial products and services providing cell and gene therapy developers with unique assays for verification of off-target editing, transgene insertion and edit-associated structural variation.
  • The combined offering from SeQure Dx and KromaTiD includes:
    Genomic Integrity Karyotyping: Confirmatory mapping of low prevalence, edit-associated chromosomal structural variation, identification of sub-clonal cell populations and monitoring of cell and gene therapy batch stability
    For more information about SeQure Dx and KromaTiD as well as updates on this partnership, please visit their respective websites at KromaTiD.com and SeQure-Dx.com .

Lung Bronchoscope Finds Unexpected Use at Fort Sanders Regional Medical Center

Retrieved on: 
Saturday, November 18, 2023
Badger, Covenant Health, Lung cancer, Life, Congestion, MD, Radiation-induced lung injury, Antibiotics

Varun Shah, MD , an interventional pulmonologist at Fort Sanders Regional Medical Center in Knoxville, TN, recently used robotic bronchoscopy to remove a nail from a man's lung.

Key Points: 
  • Varun Shah, MD , an interventional pulmonologist at Fort Sanders Regional Medical Center in Knoxville, TN, recently used robotic bronchoscopy to remove a nail from a man's lung.
  • Badger still has the nail, a reminder of what could have been a devastating lung injury and a painful procedure.
  • Fort Sanders Regional Medical Center is a member of Covenant Health , a not-for-profit healthcare delivery system serving East Tennessee and the surrounding region.
  • Located in downtown Knoxville, Fort Sanders Regional offers cutting-edge treatments and advanced technology in a multitude of services.

GENZEVA and RYLTI perform second genomic research study which yields another significant discovery

Retrieved on: 
Wednesday, November 15, 2023
Knowledge, Research, DNA, Gene, Disease, Intelligence, VUS, Genome, Diagnosis, Partnership, Bias, RKE, Antibiotics, Medical device

ROCKVILLE, Md., Nov. 15, 2023 /PRNewswire/ -- Findings from a second joint study by Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, and tech innovator RYLTI again illustrate the potential of their breakthrough process to accelerate discovery in genomic research.

Key Points: 
  • ROCKVILLE, Md., Nov. 15, 2023 /PRNewswire/ -- Findings from a second joint study by Genzeva, a leading molecular genetic laboratory that performs whole genome and clinical exome sequencing for clinical diagnostics and research, and tech innovator RYLTI again illustrate the potential of their breakthrough process to accelerate discovery in genomic research.
  • "Our second study once again illustrates that this novel process and pioneering technology for genomic analyses can uncover hidden "dark data" with insights that may never have been achievable before.
  • "Having another genomic research breakthrough with our partner Genzeva only a few months since our initial success together is very exciting.
  • RYLTI has engaged US Capital Global Partners LLC as RYLTI's financial advisor.

Dror Paley, MD Named a 2023 Florida's Most Influential Business Leaders by Florida Trend 500

Retrieved on: 
Friday, November 10, 2023
Harvard University, Mary, mother of Jesus, St. Mary's, Johns Hopkins, Hope, Medical Center, Spine, Patient, Medicine, Florida Trend, NYU, Medicover Hospitals, Medical tourism, PALM, Medical device, Nursing, Antibiotics

WEST PALM BEACH, Fla., Nov. 10, 2023 /PRNewswire-PRWeb/ -- Dr. Dror Paley, a pioneer in orthopedic medicine and a visionary leader, has been recognized once again for his exceptional contributions to the healthcare industry and the local economy. For the sixth year in a row, Dr. Paley has been named one of the 2023 Florida 500: Most Influential Business Leaders, an accolade that underscores his relentless pursuit of medical excellence and community well-being.

Key Points: 
  • For the sixth year in a row, Dr. Paley has been named one of the 2023 Florida 500: Most Influential Business Leaders , an accolade that underscores his relentless pursuit of medical excellence and community well-being.
  • Dr. Paley's leadership not only elevates the quality of healthcare but also contributes significantly to the economic and social fabric of Florida.
  • Since its inception in 2009, the Institute has seen exponential growth, now boasting a team of twenty-three top-tier surgeons in 2023.
  • Dr. Paley, along with the Institute, expresses sincere gratitude for the continued recognition by Florida Trend Magazine.